ReviewCurrent oncology reports2002
Protein kinase C inhibitors.
Review in Current oncology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 90 citations in OpenAlex.
- Trial
- Targeting Drug Chemo-Resistance in Cancer Using Natural Products.Biomedicines · 2021Review
- Therapeutic hypercapnia reduces blood-brain barrier damage possibly via protein kinase Cε in rats with lateral fluid percussion injury.Journal of neuroinflammation · 2019Article
- Article
- Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival.Oncotarget · 2016Article
- Review
- The Novel PKCθ from Benchtop to Clinic.Journal of immunology research · 2015Review
- Article
- Phorbol 12-Myristate 13-Acetate Enhances Long-Term Potentiation in the Hippocampus through Activation of Protein Kinase Cδ and ε.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2013Article
- Protein Kinase C α Modulates Estrogen-Receptor-Dependent Transcription and Proliferation in Endometrial Cancer Cells.Obstetrics and gynecology international · 2013Article
- Protein kinase C, an elusive therapeutic target?Nature reviews. Drug discovery · 2012Review
- Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011Article
- Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.Biochemical pharmacology · 2010Review
- Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.Biochemical pharmacology · 2010Article
- Stretch increases alveolar epithelial permeability to uncharged micromolecules.American journal of physiology. Cell physiology · 2006Article
- Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).Oncogene · 2004Article
- Necrotic death of Rhodococcus equi-infected macrophages is regulated by virulence-associated plasmids.Infection and immunity · 2004Article
- JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Leukemia · 2004Review
- Emerging and diverse roles of protein kinase C in immune cell signalling.The Biochemical journal · 2003Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein kinase C (PKC) is a family of serine-threonine protein kinases that are involved in signal transduction pathways that regulate growth factor response, proliferation, and apoptosis. Its central role in these processes, which are closely involved in tumor initiation, progression, and response to antitumor agents, makes it an attractive therapeutic target in cancer. Despite initial activity seen in melanoma (bryostatin and UCN-01), non-Hodgkin's lymphoma (ISIS 3521, bryostatin, and UCN-01), and ovarian carcinoma (ISIS 3521 and bryostatin) in phase I studies, single-agent activity in those phase II studies reported to date has been limited. Preclinical data highlight a role for PKC in modulation of drug resistance and synergy with conventional cytotoxic drugs. A randomized phase III study of ISIS 3521 in combination with carboplatin and paclitaxel, compared with chemotherapy alone, in advanced non-small-cell lung cancer is underway. This paper reviews the rationale for using PKC inhibitors in cancer therapy, the challenges for clinical trial design, and the recent clinical experience with modulators of PKC activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.